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Background: The effectiveness of multidisciplinary treatment in chronic widespread pain (CWP) is limited. The
considerable heterogeneity among patients is a likely explanation. Knowledge on predictors of the outcome of
multidisciplinary treatment can help to optimize treatment effectiveness. The purpose of this study was to identify
predictors of multidisciplinary treatment outcome in patients with CWP.
Methods: Data were used from baseline and 6 months follow-up measurements of a prospective cohort study of
120 CWP. Regression models were used to assess whether baseline variables predicted treatment outcome.
Outcome domains included: pain, pain interference, depression, and global perceived effect (GPE). Potential
predictors included: psychological distress, illness and self-efficacy beliefs, fear-avoidance beliefs and behaviour,
symptoms, disability, and socio-demographic factors.
Results: Greater improvement in pain was predicted by more pain at baseline and male gender. Greater
improvement in interference of pain in daily life was predicted by more interference of pain in daily life at baseline,
lower levels of anxiety, a stronger belief in personal control, less belief in consequences, male gender, and a higher
level of education. Greater improvement in depression was predicted by higher baseline values of depression,
stronger beliefs in personal control, and a higher level of education. Better outcome on GPE was predicted by less
pain, less fatigue, and a higher level of education.
Conclusion: Less anxiety, stronger beliefs in personal control, less belief in consequences, less pain, less fatigue,
higher level of education, and male gender are predictors of better outcome of multidisciplinary treatment in CWP.
Tailoring treatment to these specific patient characteristics or selecting eligible patients for multidisciplinary
treatment may further improve treatment outcome.
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Chronic widespread pain (CWP) is a syndrome of un-
known aetiology which is characterized by widespread
musculoskeletal pain, fatigue and poor sleep [1,2]. A
subcategory of patients with CWP also fulfil the criteria
of fibromyalgia (FM) [3]. Chronic widespread pain and
its associated symptoms result in a reduced quality of
life and disability, and is associated with a negative long-
term outcome [4].* Correspondence: a.d.rooij@reade.nl
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reproduction in any medium, provided the orMultidisciplinary treatment programs are recommended
in patients with FM and CWP and the associated prob-
lems [5,6]. The multidisciplinary treatment is multi-
modal and often includes the efforts of a number of
disciplines. Evidence for positive effects of multidisciplin-
ary treatment in FM has been reported [7-9]. However, on
average, the effects of multidisciplinary treatment are lim-
ited. A plausible explanation for this limited effect is the
considerable heterogeneity among patients [7,10]. It is
likely that the outcome of multidisciplinary treatment de-
pends on the specific combination of symptoms, patient
characteristics and treatment characteristics. Our sys-
tematic review revealed preliminary evidence for severall Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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outcome of multidisciplinary treatment [11]. However, the
evidence for these predictors is generally weak to incon-
clusive. Further studies are needed to establish the rela-
tionship between patients characteristics and the outcome
of multidisciplinary treatment.
Symptoms and patient characteristics may predict treat-
ment outcome, depending on the selection of patients and
the nature of treatment, as is illustrated in (Figure 1). Let
us assume that factor A (e.g. depression [12]) predicts the
persistence of symptoms and disability in untreated pa-
tients. In an unselected sample of patients and with treat-
ment not targeting factor A, factor A is expected to
predict a poor treatment outcome. Conversely, in an unse-
lected sample and with treatment targeting factor A, factor
A is not expected to predict treatment outcome: because
factor A is targeted during treatment, it is expected to
loose its predictive value. The same reasoning applies to a
sample selected for factor A. Finally, in a selected sample,
with patients with factor A excluded from treatment, fac-
tor A will not predict treatment outcome: if factor A is
not present, it cannot predict treatment outcome.
Psychological distress (depression and anxiety) is com-
monly found in CWP patients [12,13] and is a prognostic
factor for symptoms and disability [12,14]. Although pa-
tients with severe depression are typically excluded from
multidisciplinary treatment, symptoms of depression and
anxiety are common among CWP patients receiving
multidisciplinary treatment. The focus of a multidisciplin-
ary pain management program is often on cognitive and
behavioural components of pain and disability, instead of
depression and anxiety [6]. It is therefore expected that
depression and anxiety predict a poor treatment outcome,
as long as multidisciplinary treatment does not focus on
the treatment of anxiety and depression.Unselected
patients with and without 
factor A (e.g. depression)
N
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Figure 1 Selection of patients, nature of treatment and predictive valA wide variety of cognitive concepts (e.g. illness be-
liefs, self-efficacy beliefs and fear-avoidance beliefs) have
been shown to play an important role in chronic wide-
spread pain (CWP). In our previous work we found
overlap between these cognitive concepts [15]. Because
of the explorative nature of this study we treated these
concepts separately.
Illness and self-efficacy beliefs play an important role
in the adaptation of the patient to symptoms of the ill-
ness and its associated problems [16-19]. Illness beliefs
are ideas that patients hold about their illness [20,21].
Self-efficacy is defined as one’s confidence in performing
a particular behaviour and overcoming barriers to that
behaviour [22]. These beliefs are typically not a reason
to reject patients for multidisciplinary treatment, nor is
the altering of illness and self-efficacy beliefs structurally
embedded in the multidisciplinary treatment in a stan-
dardized way. These factors are therefore expected to
predict treatment outcome, as long as they are not the
focus of treatment.
Fear-avoidance beliefs and behaviour (i.e. fear of pain,
catastrophizing, and avoidance) are assumed to lead to
persistence of pain and disability [23,24]. As multidiscip-
linary treatment aims at increasing activities in daily life
despite of pain, fear avoidance beliefs and behaviour
are often altered during multidisciplinary treatment [6].
Thus, although these factors are assumed to predict per-
sistence of pain and disability, it is expected that these fac-
tors do not predict treatment outcome.
Higher levels of pain and disability are known to pre-
dict persistence of pain and disability [25-27]. Both fac-
tors are typically not a reason to exclude patients from
multidisciplinary treatment. In addition, reduction of
symptoms is not the focus of a multidisciplinary pain








ue of patient characteristic.
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level of symptoms predicts a better treatment outcome.
On the other hand because treatment is focused on the
reduction of disability and the interference of pain with
daily life, it is expected that disability looses its predict-
ive value.
Finally, socio-demographic factors may predict the
outcome of multidisciplinary treatment. Few studies [11]
have focused on socio-demographic factors so far, thus it
seems worthwhile to evaluate their predictive value.
In summary, depression, anxiety, illness beliefs, self-
efficacy beliefs, the extent of symptoms, and socio-
demographic factors are expected to predict the outcome
of multidisciplinary treatment; whereas factors related to
fear avoidance and disability are not. This study aims to
evaluate these hypotheses on predictors of the outcome of
multidisciplinary treatment in patients with CWP.
Methods
Design
The data of the present study were obtained in a longi-
tudinal observational study. The baseline measurements
(predictors and outcome measures) took place before
start of treatment (T0). The second assessment (out-
come measures) was performed 6 months after baseline
[T1]. The ethical review board of Reade in Amsterdam
approved this study. Written informed consent was
obtained from each subject.
Patients and procedure
Patients with CWP were referred by rheumatologists
and general practitioners to the pain management team
of our centre. Inclusion criteria for the study were: (i) a
diagnosis of CWP according to the American College of
Rheumatology criteria (ACR) [3]; (ii) eligible for multi-
disciplinary treatment according to the criteria the
Dutch Consensus Report of Pain Rehabilitation [28], as
assessed by both a rehabilitation physician and a psy-
chologist; these criteria require patients to experience
restrictions in daily living (e.g. sport, work) and/or psy-
chosocial functioning; and (iii) age between 18 and 75 years.
Exclusion criteria were: (i) pain resulting from known
specific pathology; (ii) not eligible for multidisciplinary
pain treatment because of a somatic disorder, social prob-
lem and/or psychiatric disorder (e.g. major depression),
or because the patient was currently involved in a legal
procedure of conflicting interest, was currently receiving
pain treatment elsewhere, or was judged by the rehabili-
tation physician and/or psychologist not to be motivated
for behavioural change; (iii) insufficient control of the
Dutch language to complete questionnaires; and (iv) re-
fusal to give informed consent.
A consecutive series of patients was included in the study.
Recruitment took 14 months. The baseline measurementswere integrated in the existing intake for the multidisciplin-
ary treatment in our centre. For the follow-up measure-
ments participants were phoned and letters were send to
encourage them to return questionnaires.
Intervention
The main goal of the intervention was to teach patients to
cope with pain and to reduce the interference of pain in
daily living. The treatment included cognitive behavioural
therapy (CBT), the acquisition of pain management skills
(e.g. goal setting, structuring of daily activities, pacing
strategies, ergonomics), physical training (e.g. exercise), re-
laxation training, education about neuro-physiology and
medication management, and assertiveness training. The
components of the multidisciplinary treatment were in
line with the core elements of multidisciplinary treatment
in CWP [6,8]. In the treatment program ‘illness beliefs and
self- efficacy beliefs’ were not explicit or standardized al-
tered. The treatment was tailored to the patients personal
goals and was performed in groups and on individual
basis. Group treatment consisted of seven consecutive
weeks of treatment, seven hours a week and was divided
into two sessions a week of multidisciplinary treatment.
Individual treatment was offered during a period of four
to six months with a variable frequency per patient. The
multidisciplinary team involved rehabilitation physicians,
physiotherapists, occupational therapists, psychologists,
and social workers. The multidisciplinary team discussed
the treatment progress of patients during regular team
meetings.
Outcome measurements
Four outcome domains were defined in accordance with
the recommendations of the Initiative on Methods,
Measurement, and Pain Assessment in Clinical Trials
(IMMPACT), i.e. pain, physical functioning, emotional
functioning, and global perceived effect [29].
Pain was assessed with the Numerical Rating Scale
Pain (NRS) (range 0–10). The endpoints of the scale are
no pain and worst possible pain. Adequate psychometric
properties have been documented [30].
Physical functioning was assessed with the Multidi-
mensional Pain Inventory (MPI), subscale interference.
The MPI consists of 13 empirically derived scales that
measure different pain-related aspects. The subscale
interference assesses patients perceptions about how
pain interferes with their daily lives. A higher score of
interference (range 0 to 54) means more interference of
pain in daily life. The MPI has been widely used with di-
verse chronic pain samples and has good psychometric
properties [31].
Emotional functioning was assessed with the Beck
Depression Inventory II (BDI-II). The BDI-II is a self-
reported measure that assesses the cognitive, affective,
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questions ask about symptoms and attitudes and are
rated from 0 to 3 in terms of intensity. A higher score
on the BDI-II (range 0 to 63) indicates more depressive
symptoms. The BDI-II has been shown to have adequate
psychometric properties [34].
Global perceived effect (GPE) due to treatment was
assessed with a 7-point Likert scale ranging from the com-
plaints in global health ‘have disappeared’ to ‘very much
deteriorated’. The scale was dichotomized in 0 = no
change/worse and 1 = improved.
Potential predictors of treatment outcome
Psychological distress
Depression was assessed with the BDI-II. The BDI-II has
been described previously.
Psychological functioning was assessed with the Dutch
version of the Symptom CheckList (SCL90). The SCL 90 is
a self reported questionnaire and measures psychological
and physical distress. The items are rated on a 5 point scale:
1 (not at all) to 5 (very much). The total score of the SCL
90 (range 90 to 450) reflects psychoneurotism, where a
higher score means a higher degree of psychoneuroticism.
The Dutch version of the SCL-90 has been shown to have
adequate psychometric properties [35].
Anxiety was assessed with the Hospital Anxiety Depres-
sion Scale (HADS), subscale anxiety. The scale measures
anxiety based on 7 items. A higher score (range 0 to 21)
means a higher level of anxiety. The HADS is widely used
and have adequate psychometric properties [36].
Illness and self-efficacy beliefs
Illness beliefs were assessed with the Revised Illness Per-
ceptions Questionnaire (IPQ-R). Seven subscales of the
Revised Illness Perceptions Questionnaire (IPQ-R) were
used to measure beliefs about 1)‘consequences’- expected
effects and outcome of the illness; 2)‘coherence’- patient’s
logical and complete understanding of the illness;
3)‘emotional representations’- negative emotional reactions
like anger and fear related to the illness; 4) ‘timeline’-
chronic timeline expectancies of the illness; 5) ’timeline
cyclical’- expectancies on the variability of the illness;
6)‘personal control’- extent to which patients believe they
can control the illness; and 7) ‘treatment control’- belief in
treatment and recommended advice. Items in these scales
are rated on a 5-point Likert scale ranging from ’strongly
disagree’ to ‘strongly agree’. Higher scores on personal
control (range 6 to 30), treatment control (range 5 to 25)
and low scores on illness coherence (range 5 to 25) dem-
onstrate positive beliefs about the controllability of the ill-
ness and a personal understanding of the illness,
respectively. High scores on timeline (range 6 to 30), time-
line cyclical (range 4 to 20), consequences (range 6 to 30)
and emotional representation (range 6 to 30) demonstratestrongly held beliefs about the chronicity of the illness, the
cyclical nature of the illness, negative consequences of the
illness, and more emotional representations, respectively
[37,38]. The validity and reliability of the IPQ-R have been
documented [39].
Self-efficacy beliefs were measured with the Dutch
General Self-efficacy Scale (DGSS). General self-efficacy
is defined as a broad and stable sense of personal
competence to deal effectively with a variety of stress-
ful situations [40]. The DGSS consists of 10 items,
and are answered on a four point scale, ranging from
‘not at all true’ to ‘exactly true’, with a higher score
(range 10 to 40) indicating a higher self-efficacy. The
psychometric properties of the DGSS have been docu-
mented [41,42].Fear-avoidance beliefs and behaviour
Fear-avoidance was measured with the Tampa Scale of
Kinesiophobia (TSK). The TSK measures self-reported
fear of movement and (re) injury. The scale consists of
17 items and the items are evaluated on a 4-point Likert
scale, ranging from ‘strongly disagree’ to ‘strongly agree’.
A higher score (range 17 to 68) indicates a higher degree
of fear-avoidance [43].
Avoidance behaviour was measured with the Pain Coping
Inventory (PCI), subscale resting. The PCI subscale resting
assesses the level to which patients avoid physical activity.
The scale consists of five items, and is rated on a 4-point
Likert scale ranging from ‘rarely or never, to very fre-
quently’. A higher score (range 5 to 20) on the PCI means
more avoidance. Adequate psychometric properties have
been documented [44].
Catastrophizing was measured with the Dutch adapta-
tion of the Coping Strategy Questionnaire (CSQ), subscale
catastrophizing. The subject indicated to what extent this
particular coping strategy was utilized, based on 6 items.
A higher score indicated (range 0 to 60) that the subject
made more use of this coping style. The validity and reli-
ability of the CSQ have been documented [45].Symptoms
Pain was assessed with the NRS. The NRS has been de-
scribed previously (see above).
Impact of FM was assessed with the Fibromyalgia Im-
pact Scale (FIQ). The scale evaluates physical functioning,
work status, depression, anxiety, sleep, pain, stiffness, fa-
tigue, and well-being. A higher score (range 0 to 80) indi-
cate a higher impact of FM. The FIQ has been widely used
with diverse chronic pain samples, and has good psycho-
metric properties [46].
Fatigue was measured with the subscale fatigue of the
FIQ. A higher score indicate a higher level of fatigue.
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Physical functioning was assessed with the MPI -subscale
interference. The MPI has been described previously
(see above).
General activity was measured with the MPI -subscale
general activity. The subscale general activity (range 0 to
18) assesses the frequency of activity of household
chores, outdoor work, activities away from home, and
social activities.Socio-demographic variables
Socio-demographic variables were recorded of each pa-
tient: age was rated in years and gender, partnership,
ethnicity and level of education were coded as dummy
variables.Statistical analyses
Descriptive statistics for baseline patient characteristics
were tabulated as means (SD) or medians (IQR) if data
was not normally distributed. Patient characteristics (i.e.
age, pain, interference of pain and depression) of partici-
pants with complete datasets (N=120) and drop-outs
(N=13) were compared and analyzed with a Mann–
Whitney U test. Differences between T0 and T1 scores
on the outcome measures BDI-II, MPI- subscale inter-
ference and NRS pain were analyzed using two tailed
paired t–tests (with a significance level of P < 0.05). Uni-
variate and multiple regression analyses were performed
to evaluate the predictors of treatment outcome. The
change in the outcome variables and GPE were entered
as the dependent variable. The potential predictors were
entered as independent variables. First an explorative
univariate regression analysis was performed with each
potential predictor of the outcome of multidisciplinary
treatment. Variables that reached a statistical signifi-
cance below 0.20 were selected as potential predictors
for the multivariate analyses. The bivariate correlation
coefficients were computed to establish the relationships
between the selected predictors of the outcome variables
that reached a statistical significance at P < 0.20. When
correlations coefficients of r > 0.70 were found, one of
the variables was excluded from the model, to avoid
multicolinearity. Multiple linear regression analyses
(backward selection) were performed to identify predic-
tors of change in outcome on NRS pain, MPI- subscale
interference and BDI-II. A multiple logistic regression
analysis (backward selection) was performed to identify
predictors of GPE. A significance level of P < 0.05 was
used to include a predictor in the final model. In sec-
ondary analyses, the variable ‘treatment frequency’ was
forced into the final model of the multiple regression
analysis to determine whether treatment frequency was
a potential confounder of the found relationships.Results
Study population
Of the 361 patients referred to and evaluated by the pain
management team, 165 patients fulfilled the inclusion
criteria for this study. Of these patients, 138 consented
to participate in the study. Reasons for not participating
were: dyslexia, not interested in completing the neces-
sary paperwork, too busy or no specific reason. Of these
138 participants, 133 participants provided data at T0.
Reasons for missing cases at this stage were: withdrawal
from treatment (n=3) and no specific reason (n=2). One
hundred twenty participants provided data at T1. Rea-
sons for missing cases at this stage were: no further con-
sent for participation in the study (n=3) or no specific
reason (n=10). Participants who dropped-out of the
study at T1 did not differ significantly from participants
who completed the measurements at T1, except for de-
pression (Mdrop-out = 26.23, SD = 7.36; Mparticipants = 20.78,
SD = 8.85; P = 0.02). Baseline characteristics of the partici-
pants are shown in Table 1.
Changes in depression, interference of pain, pain and
global perceived effect
Table 2 shows T0 and T1 scores on the outcome mea-
sures. Statistically significant improvements after treat-
ment were found for interference of pain (MPI) (P=
0.02) and depression (BDI-II) (P< 0.001). Forty-eight
percent of the patients improved on GPE.
Predictors of outcome
The results of the univariate linear regression analyses
are shown in Table 3. Predictors with a relationship with
the outcome measure of P < 0.20 were used for multiple
regression analyses. The correlation coefficients between
the potential predictors of the outcome measure pain
ranged from .27 (i.e. pain (NRS) and depression (BDI))
to .52 (i.e. pain (NRS) and the impact of fibromyalgia
(FIQ)). The relationships between the potential predic-
tors of the outcome measure interference of pain ranged
from .18 (self-efficacy (DGSS) and beliefs in conse-
quences (IPQ)) to .67 (i.e. psychological functioning
(SCL 90) and anxiety (HADS)). In addition, the relation-
ships between the potential predictors of the outcome
measure depression ranged from .21 (i.e. beliefs in time-
line (IPQ) and resting (PCI)) to -.31 (i.e. beliefs in
personal control (IPQ) and resting (PCI)). Finally, rela-
tionships between the potential predictors of the out-
come measure global perceived effect ranged from -.20
(i.e. timeline beliefs (IPQ) and treatment control (IPQ)) to
.62 (i.e. fatigue (FIQ) and impact of fibromyalgia (FIQ)).
Only variables that showed a statistically significant associ-
ation (at P < 0.05) with change scores in the outcome
measures were included in the final model. The results of
the multiple linear regression analyses are shown in
Table 1 Baseline patient characteristics
Variable Value Range N
Pain (NRS), mean (SD) 6.1 (2.1) 1-10 120
Interference (MPI), mean (SD) 4.1 (1.1) 1.1-5.9 120
Depression (BDI-II), mean (SD) 20.8 (8.9) 4 –51 120
Psychological functioning (SCL 90), mean (SD) 179.3 (48.6) 108-409 116
Anxiety (HADS), mean (SD) 8.1 (3.6) 0-17 116
Emotional representation (IPQ), mean (SD) 19.2 (4.7) 8-30 120
Coherence (IPQ), mean (SD) 15.0 (4.8) 6-25 119
Consequence (IPQ), mean (SD) 20.9 (4.4) 10-30 120
Personal control (IPQ), mean (SD) 18.6 (4.3) 6-30 120
Treatment control (IPQ), mean (SD) 16.2 (2.9) 5-25 120
Timeline cyclical (IPQ ), mean (SD) 15.3 (3.2) 4-20 120
Timeline (IPQ), mean (SD) 23.6 (3.6) 12-30 120
General self efficacy (DGSS), mean (SD) 2.9 (.6) 1.2- 4.1 120
Fear avoidance (TSK), mean (SD) 36.5 (7.5) 21-56 120
Avoidance behavior (PCI), mean (SD) 2.5 (.6) 1-4 120
Catastrophizing (CSQ), mean (SD) 23.9 (11.0) 1.0-50.0 120
Impact of FM (FIQ), mean (SD) 51.8 (11.0) 25.8 – 77.8 120
Fatigue (FIQ), median (IQR) 8.0 (7.25; 10.0) 4-10 120
Activity level (MPI), mean (SD) 2.6 (.9) 0-5.1 120
Gender, Female (%) 95 114
Age 45.0 (10.3) 21-69 120
Partnership, Yes (%) 51 n= 61
Ethnicity (%)
Native 71 n= 85
Western non native 13 n= 15
Non western non native 17 n= 20
Education (%)
Primary 18 n= 21
Secondary 50 n= 59
High 33 n= 39
Values are means (SD), median (IQR) or percentages. SD= standard deviation, IQR= interquartile range. BDI-II= Beck Depression Inventory, CSQ= Coping Scale
Questionnaire, HADS= Hospital Anxiety Depression scale, DGSS= Dutch General Self efficacy Scale, FIQ= Fibromyalgia Impact Questionnaire, IPQ= Illness
Perception Questionnaire, MPI= Multidimensional Pain Inventory, NRS= Numerical Rating Scale, PCI= Pain Coping inventory, SCL 90= Symptom checklist,
TSK= Tampa scale for Kinesiofobia.
Table 2 Outcome measures before and after intervention
T0 T1 P value
Pain (NRS) 6.08 (2.08) 6.08 (1.89) 0.96
Interference (MPI) 4.07 (1.06) 3.87 (1.13) 0.02




Values are means (SD), or percentages, SD= standard deviation.
T0= before intervention, T1= follow up at 6 months.
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ated with more pain (NRS) at baseline (P < 0.001) and
male gender (P = 0.02). Greater improvement in interfer-
ence of pain in daily life (MPI) was associated with more
interference of pain (MPI) at baseline (P < 0.001), less anx-
iety (HADS) (P = 0.03), stronger beliefs in personal con-
trol (IPQ) (P < 0.004), less beliefs in consequences (IPQ)
(P < 0.001), male gender (P = 0.02), and a higher level of
education (P= 0.003, P = 0.03). Greater improvement in
depression (BDI-II) was associated with more depressive
symptoms at baseline (P < 0.001), stronger beliefs in
Table 3 Results of univariate regression analyses of change in pain, interference of pain, depression and GPE
NRS Pain MPI Interference BDI- II Depression GPE
B β P B β P B β P Odds P
Pain (NRS) -.53 -.56 .00 .04 .10 .27 .05 .01 .89 .70 .00
Interference (MPI) -.12 -.06 .49 -.26 -.32 .00 .04 .01 .95 .70 .05
Depression (BDI-II) -.04 -.17 .06 .00 .04 .69 -.28 -.33 .00 1.00 .84
Psychological functioning (SCL 90) -.00 -.07 .45 .00 .17 .06 -.02 -.12 .21 1.00 .98
Anxiety (HADS) -.06 -.10 .27 .04 .17 .07 -.24 -.11 .23 1.06 .24
Emotional representation (IPQ) .01 .01 .88 .01 .06 .52 -.15 -.10 .31 .98 .65
Coherence (IPQ) .04 .10 .30 .02 .13 .15 .14 .09 .33 .10 .90
Consequences (IPQ) -.04 -.08 .39 .03 .15 .10 -.01 -.00 .97 .96 .41
Personal control (IPQ) -.02 -.04 .70 -.03 -.16 .09 -.51 -.30 .00 1.14 .01
Treatment control (IPQ) -.06 -.09 .35 -.19 -.08 .42 -.19 -.08 .42 1.15 .04
Timeline cyclical (IPQ) .05 .08 .37 -.02 -.06 .51 .07 .03 .75 1.18 .01
Timeline (IPQ) -.00 -.01 .93 .03 .12 .20 .31 .15 .11 .97 .54
General self efficacy (DGSS) .36 .11 .23 -.27 -.19 .04 .99 .08 .41 .97 .93
Fear avoidance (TSK) -.03 -.10 .29 .00 .02 .85 .07 .07 .45 1.02 .52
Avoidance behaviour (PCI) .07 .02 .81 .02 .02 .87 1.91 .16 .09 .90 .71
Catastrophizing (CSQ) -.02 -.10 .30 0.00 -.00 .99 -.03 -.04 .67 1.00 .81
Impact of FM (FIQ) -.04 -,21 .02 .01 .10 .27 -.00 -.00 .98 .94 .00
Fatigue (FIQ) -.05 -.04 .65 .05 .08 .39 .08 .02 .87 .68 .00
Activity level (MPI) -.10 -.04 .65 -.04 -.04 .67 .47 .05 .57 1.46 .10
Gender 1.40 .16 .09 .60 .15 .10 3.25 .10 .30 .17 .12
Age -.03 -.17 .07 -.02 -.20 .03 .06 .09 .34 .98 .30
Partnership -.18 -.05 .61 .05 .03 .75 -.41 -.03 .77 1.07 .85
Ethnicity
Native vs Western non native -.20 -.04 .71 -.19 -.08 .43 −2.97 -.13 .16 .59 .36
Native vs non Western non native -.32 -.06 .51 .02 .01 .94 1.53 .08 .41 .48 .15
Education
Primary vs secondary .09 .02 .87 -.50 -.29 .02 −4.69 -.31 .02 2.96 .05
Primary vs high -.18 -.04 .74 -.39 -.22 .09 −5.71 -.36 .01 2.38 .14
B = unstandardized regression coefficient, β = standardized regression coefficient, P = P value, in bold: P values ≤ 0.20. BDI-II= Beck Depression Inventory,
CSQ= Coping Scale Questionnaire, DGSS= Dutch General Self efficacy Scale, FIQ= Fibromyalgia Impact Questionnaire, GPE= Global perceived effect, IPQ= Illness
Perception Questionnaire, MPI= Multidimensional Pain Inventory, NRS= Numerical Rating Scale, PCI= Pain Coping inventory, SCL 90= Symptom checklist,
TSK= Tampa scale for Kinesiofobia.
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tion (P = 0.02, P = 0.04). Better global perceived effect
was associated with less pain (NRS) (P = 0.01), less
fatigue (FIQ) (P = 0.03), and a higher level of education
(P = 0.03). The explained variance (R2) for the final
models ranged from 25.7% to 38.1%. In summary, five of
our eight hypotheses were confirmed while one hypoth-
esis was partly confirmed (see Table 5).
In the secondary analyses, adjustment for treatment
frequency in the multiple variable models only affected
the model of GPE. After adjustment, global perceived
effect was only associated with pain (NRS) (OR = .72;
95% CI, .58 to 90), fatigue and education were no longer
factors in the final model.Discussion
The present results show that psychological distress (i.e.
anxiety), illness beliefs (i.e. beliefs in personal control
and consequences), symptoms of pain and fatigue, and
socio-demographic factors (i.e. gender and level of edu-
cation) are associated with the success of multidisciplin-
ary treatment in patients with CWP. In addition, for all
outcome measures, higher baseline values (i.e. indicating
a worse health status) were associated with greater im-
provement in outcome.
In line with one of our hypotheses, we found that
higher levels of anxiety at baseline were associated with
less improvement in interference of pain with daily life
after multidisciplinary treatment. To our knowledge, this
Table 4 Results of multiple regression analyses of change in pain, interference of pain, depression and GPE
NRS Pain MPI Interference of pain BDI II Depression Global perceived effect
N = 120 N=113 N = 116 N = 119
B (95% CI) β P B (95% CI) β P B (95% CI) β P Odds (95% CI) P
Baseline value -.53 (−.67 to -.39) -.57 <0.001 -.55 (−.70 to -.39) -.68 <0.001 -.30 (−.44 to -.16) -.35 <0.001
Anxiety (HADS) .043 (.00 to .08) .18 0.03
Personal control (IPQ) -.05 (−.08 to-.02) -.25 0.004 -.53 (−.82 to -.23) -.30 <0.001
Consequence (IPQ) .08 (.04 to .11) .40 <0.001
Pain (NRS) .75 (.60 to .93) 0.01
Fatigue (FIQ) .72 (.53 to .96) 0.03
Gender 1.54 (.22 to 2.86) .17 0.02 .74 (.11 to 1.38) .18 0.02
Education
Primary vs secondary -.57 (−.93 to -.20) -.34 0.003 −4.09 (−7,57 to -.62) -.27 0.02 3.83 (1.14 to 12.86) 0.03
Primary vs high -.43 (−.82 to -.04) -.24 0.03 −3.93 (−7.71 to -.15) -.25 0.04 2.52 (.73 to 8.67) 0.14
R2 34.6% 38.1% 25.7%
B = unstandardized regression coefficient, 95% CI = 95% confidence interval of B, β = standardized regression coefficient, P = P value global perceived effect:
0 = no change/worse, 1 = improved, gender; 0 = male, 1= female. β negative: greater improvement in BDI- II, NRS pain and MPI interference. β positive: less
improvement in BDI- II, NRS pain and MPI interference. Higher scores on the HADS, IPQ, NRS pain and FIQ, indicate more anxiety, higher beliefs in personal
control, higher beliefs in consequence, more pain and fatigue.
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http://www.biomedcentral.com/1471-2474/14/133is the first study that has focused on anxiety as a potential
predictor of multidisciplinary treatment outcome in pa-
tients with CWP. These results indicate that higher levels
of anxiety are a barrier to effective multidisciplinary treat-
ment. Contrary to our hypothesis derived from the lite-
rature [11] that depression would be a predictor of
treatment outcome, we found no evidence to support this.
A selective dropout from the study of patients with more
depressive symptoms might explain this. In addition, ex-
clusion of severely depressed patients might have contrib-
uted to depression failing to predict outcome in the
present study. Alternatively, although depression was not
specifically targeted during treatment, the level of depres-
sion may have been influenced by various components of
the pain management program (e.g. CBT, goal setting and
structuring of daily life) and therefore may have lost its
predictive value.Table 5 Summary of hypothesis testing
Hypotheses
Depression predicts a poor outcome of multidisciplinary treatment
Anxiety predicts a poor outcome of multidisciplinary treatment
Negative illness beliefs predict a poor outcome of multidisciplinary treatmen
Low self-efficacy beliefs predict a poor outcome of multidisciplinary treatmen
High level of symptoms predict a poor outcome of multidisciplinary treatme
Demographic factors (age, gender, partnership, ethnicity and education) pred
of multidisciplinary treatment
Fear avoidance beliefs and behaviour do not predict the outcome of multidi
Level of disability does not predict the outcome of multidisciplinary treatmenAs expected, stronger beliefs in personal control were
associated with greater improvement of depression and
interference of pain with daily life after multidisciplinary
treatment. In addition, less belief in the negative conse-
quences of the illness appeared to be associated with a
greater improvement in interference of pain with daily
life. These results are congruent with those of Glattacker
et al. [47], who demonstrated that positive illness beliefs
(e.g. less belief in consequences) are associated with a
greater improvement in treatment outcome in women
with fibromyalgia. Contrary to our expectations and our
preliminary evidence [11], we did not find self-efficacy
to predict treatment outcome. This might be explained
by the operationalization of the concept of self-efficacy.
In this study we were interested in the predictive value
of general self-efficacy beliefs (i.e. defined as a broad and






ict the outcome Partly (i.e. gender and education)
sciplinary treatment Yes
t Yes
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http://www.biomedcentral.com/1471-2474/14/133domain-specific self-efficacy. It is possible that general
self-efficacy at baseline is not directly related to treat-
ment outcome, while this might be true for domain-
specific self-efficacy beliefs [48].
Fear-avoidance beliefs and behaviour did not predict the
outcome of multidisciplinary treatment. We expected that
fear-avoidance beliefs and behaviour would not predict
treatment outcome because they are often targeted during
multidisciplinary treatment to increase daily activity and
therefore lose their predictive value.
As expected, patients with lower levels of pre-
treatment pain and fatigue reported a better global treat-
ment effect. This suggests that patients with pronounced
symptoms benefit less from standard multidisciplinary
treatment including CBT. Thieme et al. [49] also found
that patients with pronounced pain benefit less from
multidisciplinary treatment which includes CBT. Better
results have been found with specific operant behaviour
therapy (OBT) treatments which focus specifically on the
modification of pain behaviour: pain behaviour is not en-
dorsed or rewarded. As expected, physical functioning
was not a predictor of treatment outcome. This can be
explained through the fact that the focus of multidiscip-
linary treatment is on the reduction of disability and
interference of pain with daily life, whereby physical func-
tioning looses its predictive value.
Finally, the results indicate that socio-demographic
factors predict the outcome of multidisciplinary treat-
ment. Male gender predicts a greater improvement in
interference of pain with daily life and post treatment
pain. Since our study population only included 5 men,
this finding requires further investigation. In addition, a
higher level of education predicts a greater improve-
ment in depression, interference of pain with daily life
and a better global perceived effect. These results are in
line with the findings of other studies in FM patients
[50,51]. Our findings might be explained by low health
literacy: low educational status is correlated with low
health literacy in patients with chronic diseases [52,53].
In accordance with our clinical experience, patients
with a lower level of education may have difficulty in
fully understanding the presented material and thus ap-
plying it in practice.
Another finding was that higher baseline values of
outcome measurements (indicating more depressive
symptoms, higher interference of pain with daily life,
and more pain) were associated with greater effects of
multidisciplinary treatment. This can be explained by
a methodological effect (i.e. regression to the mean)
[54]: patients with high baseline scores can show more
improvement than patients with already low baseline
scores.
There are several limitations in our study that warrant
discussion. We chose our predictors based on theoryand previous research instead of an explorative ap-
proach. However, this still led to a relatively large num-
ber of predictors which we reduced using statistical
pre-selection. This procedure may have caused some
instability in our results [55]. Furthermore, we did not
include a control group and are thus not able to con-
clude that changes in outcome measurements were the
result of the multidisciplinary treatment. Evaluating
predictors of change in uncontrolled studies does not
make it possible to distinguish between predictors of
natural course of a disease and predictors of successful
treatment. Whether or not a distinction in predictors
exists can only be studied in randomized controlled
trials aiming at investigating the effectiveness of multi-
disciplinary treatment in patients with CWP.
Although the improvements in outcome were small on
a group level, individual differences in patients charac-
teristics were related to the differences in the effect of
treatment outcome. For multidisciplinary treatment this
suggests that it is important to find out which clinical
characteristics are present in each patient with CWP.
Tailoring treatment or strategies to specific patient char-
acteristics may further improve multidisciplinary treat-
ment outcome.
The present results may have implications for treat-
ment planning. Patients with pronounced psycho-
logical distress (i.e. anxiety), or negative illness beliefs
might benefit from treatment components which spe-
cifically focus on the treatment of psychological dis-
tress or maladaptive thoughts about their illness,
respectively. For these patients it might be worthwhile
to add these specific components to multidisciplinary
treatment. In addition, as pronounced symptoms pre-
dicted poorer treatment outcome, an approach based
on operant behaviour therapy may be more effective
than an approach based on cognitive behaviour ther-
apy [49]. With regard to the finding that education
predicted treatment outcome, it might be worthwhile
to adjust multidisciplinary treatment to the cognitive
ability of the patient. Alternatively, when there is no
option to adapt the treatment program to the patients
personal needs, selection of eligible patients (i.e. pa-
tients with less anxiety, more positive illness beliefs,
less pronounced symptoms and/or a higher educa-
tional level) might also improve the effectiveness of a
multidisciplinary treatment. Finally, little is known
about the influence of treatment intensity on treat-
ment response. Adjustment of treatment frequency of
the results did not influence the relationships between
predictors and outcome measurements, with the ex-
ception of GPE. Additional studies are necessary to
develop a greater understanding of the influence of
treatment intensity on predictors and multidisciplinary
treatment outcome in patients with CWP.
de Rooij et al. BMC Musculoskeletal Disorders 2013, 14:133 Page 10 of 11
http://www.biomedcentral.com/1471-2474/14/133Conclusion
In conclusion, less anxiety, stronger beliefs in personal
control, lower beliefs in consequences, less pain, less fa-
tigue and a higher level of education are predictors of
greater improvement in the outcome of multidisciplinary
treatment. Tailoring treatment to specific patient charac-
teristics or selecting eligible patients for multidisciplin-
ary treatment may further improve treatment outcome.
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